Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
16.28
+0.49 (3.10%)
At close: Sep 2, 2026, 4:00 PM EDT
16.16
-0.12 (-0.71%)
Pre-market: Sep 3, 2026, 7:28 AM EDT
Generate Biomedicines Revenue
Generate Biomedicines had revenue of $6.31M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $26.48M. In the year 2025, Generate Biomedicines had annual revenue of $31.89M with 55.89% growth.
Revenue (ttm)
$26.48M
Revenue Growth
+55.89%
P/S Ratio
78.90
Revenue / Employee
$84,881
Employees
312
Market Cap
2.09B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.89M | 11.43M | 55.89% |
| Dec 31, 2024 | 20.46M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
GENB News
- 6 days ago - Generate Biomedicines price target raised to $30 from $25 at H.C. Wainwright - TheFly
- 7 days ago - Generate Biomedicines falls -16.7% - TheFly
- 7 days ago - Generate Biomedicines falls -11.0% - TheFly
- 8 days ago - Generate Biomedicines rises 17.7% - TheFly
- 27 days ago - Generate Biomedicines reports Q2 EPS (52c), consensus (49c) - TheFly
- 4 weeks ago - Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Generate Biomedicines Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Generate Biomedicines Earnings release: Q2 2026 - Filings